Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV003 Vaccine Efficacy Against DENV-2 and DENV-3 Challenge
NCT03416036Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Butantan-DV in dengue fever (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of rDEN2Δ30-7160 viremia at Month 1, Frequency of rDEN3Δ30 viremia at Month 1 and 3 more. Started Nov 2017; status: completed.
02
Drugs
Butantan-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03416036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416036.